MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1159/000525742

Медицинская библиотека · Oncology · 2022

Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.

Yasuoka Hidetoshi, Naganuma Atsushi, Kurihara Eishin, Kobatake Tsutomu, Ijima Masashi, Tamura Yuki, Suzuki Yuhei, Hoshino Takashi, Ishida Fumiya, Hosaka Hisashi, Hatanaka Takeshi, Yoshida Sachiko, Aihara Ryusuke, Hosouchi Yasuo, Ishii Norihiro, Araki Kenichiro, Shirabe Ken, Uraoka Toshio, Kakizaki Satoru

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

This retrospective study investigated the efficacy and safety of nano-liposomal irinotecan (nal-IRI) plus 5-fluorouracil/L-leucovorin (5-FU/l-LV) treatment in the second-line or later setting for advanced pancreatic cancer under real-world conditions.

METHODS

Between June 2020 and September 2021, a total of 44 patients with unresectable advanced pancreatic cancer treated with nal-IRI + 5-FU/l-LV in our affiliated hospitals were included. The prognosis, predictive factors (including systemic inflammation-based prognostic indicators), and adverse events were investigated.

RESULTS

The median age was 68 (interquartile range 62-73) years old, and 22 patients (50.0%) were male. Concerning tumor factors, 9 patients (20.5%) had local advanced disease and 35 patients (79.5%) had metastases. Twenty-five of the 44 patients were receiving second-line treatment, and 19 were receiving third-line or later treatment. The median overall survival (OS) and progression-free survival were 9.0 (range, 0.7-15.4) months and 4.4 (range, 0.6-15.4) months, respectively. The overall response rate was 5.3%. The disease control rate was 44.7%. Patients with a neutrophil-to-lymphocyte ratio of ≥2.7 had a significant risk of a poor OS (HR = 0.275, p = 0.017). Adverse events were manageable, although gastrointestinal symptoms and neutropenia were observed. The most common grade ≥3 adverse event was neutropenia, which was reported in 20% of patients.

CONCLUSIONS

Nal-IRI + 5-FU/l-LV therapy was considered to be a useful regimen as second-line or later treatment for unresectable advanced pancreatic cancer, even in clinical practice.

Для цитирования: Yasuoka Hidetoshi, Naganuma Atsushi, Kurihara Eishin, Kobatake Tsutomu, Ijima Masashi, Tamura Yuki, Suzuki Yuhei, Hoshino Takashi, Ishida Fumiya, Hosaka Hisashi, Hatanaka Takeshi, Yoshida Sachiko, Aihara Ryusuke, Hosouchi Yasuo, Ishii Norihiro, Araki Kenichiro, Shirabe Ken, Uraoka Toshio, Kakizaki Satoru. Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study.. Oncology. 2022. DOI: 10.1159/000525742.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.